Feprazone

CHEMBL1452696 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
320.4 g/mol
LogP
3.1
Phase
4

This is a nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, swelling, and fever by blocking certain chemical messengers in the body. It is used for conditions involving inflammation such as arthritis. Like other NSAIDs, it may cause stomach irritation with prolonged use.

분자량

320.4000 g/mol

LogP

3.10

TPSA

40.60 Ų

리핀스키 5의 법칙

통과

작용 기전

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O

InChI

InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3

Molecular Formula

C20H20N2O2

HBD / HBA

- / 2

회전 가능 결합

4

무거운 원자

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This is a nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, swelling, and fever by blocking certain chemical messengers in the body. It is used for conditions involving inflammation such as arthritis. Like other NSAIDs, it may cause stomach irritation with prolonged use.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Feprazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1452696. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 35455. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.